Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

Sonja Merkesdal

Division of Clinical Immunology and Rheumatology

Working Group for Health Economics and Clinical Epidemiology

Hannover Medical School

Carl-Neuberg-Strasse 1

Germany

[email]@mh-hannover.de

Name/email consistency: high

[Claim this account]

Affiliations

Division of Clinical Immunology and Rheumatology, Working Group for Health Economics and Clinical Epidemiology, Hannover Medical School, Carl-Neuberg-Strasse 1, Germany. 2010
Division of Rheumatology, Hannover Medical School, Center for Health Economics, University of Hannover, Germany. 2001 - 2005
Hannover Medical School, Division of Rheumatology, Carl-Neuberg-Str. 1, 30623 Hannover, Germany. 2004

References

Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure. Merkesdal, S., Kirchhoff, T., Wolka, D., Ladinek, G., Kielhorn, A., Rubbert-Roth, A. Eur. J. Health. Econ (2010) [Pubmed]
Indirect cost assessment in patients with rheumatoid arthritis (RA): comparison of data from the health economic patient questionnaire HEQ-RA and insurance claims data. Merkesdal, S., Ruof, J., Huelsemann, J.L., Mittendorf, T., Handelmann, S., Mau, W., Zeidler, H. Arthritis Rheum. (2005) [Pubmed]
Prediction of costs-of-illness in patients with low back pain undergoing orthopedic outpatient rehabilitation. Merkesdal, S., Mau, W. Int. J. Rehabil. Res (2005) [Pubmed]
TNF-blocking therapy in rheumatoid arthritis and ankylosing spondylitis: why is cost-effectiveness a major issue?. Merkesdal, S., Zeidler, H. Curr. Rheumatol. Rep (2005) [Pubmed]
Cost-effectiveness of TNF-alpha-blocking agents in the treatment of rheumatoid arthritis. Merkesdal, S., Ruof, J., Mittendorf, T., Zeidler, H. Expert. Opin. Pharmacother (2004) [Pubmed]
Indirect medical costs in the first 3 years of rheumatoid arthritis: comparison of current methodological approaches. Merkesdal, S., Ruof, J., Mittendorf, T., Zeidler, H., Mau, W. Expert. Rev. Pharmacoecon. Outcomes. Res (2002) [Pubmed]
Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis. Merkesdal, S., Ruof, J., Huelsemann, J.L., Schoeffski, O., Maetzel, A., Mau, W., Zeidler, H. J. Rheumatol. (2001) [Pubmed]

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.